Top

Breast Cancer

Published in:

01-04-2013 | Original Article

Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)

Authors: Mehmet Artac, Hakan Bozcuk, Aysel Kıyıcı, Orhan Onder Eren, Melih Cem Boruban, Mustafa Ozdogan

Published in: Breast Cancer | Issue 2/2013

Abstract

Introduction

Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs).

Methods

Sixty MBC patients treated with first line hormonal therapy were enrolled in this study.

Results

Median age was 51 years (range 28–75). Median leptin level was 19400 pg/ml (1970–91900) and estradiol level 29.6 pg/ml (4.0–181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was ≥19400 pg/ml (HR = 0.38; 95% CI: 0.16–0.91).

Conclusions

This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.

Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–42.PubMedCrossRef

Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(Suppl):S116–24.PubMedCrossRef

Longcope C, Baker R, Johnston CC Jr. Androgen and estrogen metabolism: relationship to obesity. Metabolism. 1986;35:235–7.PubMedCrossRef

Long JR, Shu XO, Cai Q, Wen W, Kataoka N, Gao YT, et al. CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int J Obes (Lond). 2007;31(3):418–23.CrossRef

Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003;278:28668–76.PubMedCrossRef

Geisler C, Haynes B, Ekse D, Dowsett M, Lønning PE. Total body aromatization in postmenapozal breast cancer patients is strongly correlated to plasma leptin levels. J Streoid Biochem Mol Biol. 2007;104:27–34.CrossRef

Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int J Oncol. 2002;21:1285–92.PubMed

Kim Y, Kim SY, Lee JJ, Seo J, Kim YW, Koh SH, et al. Effects of the expression of leptin and leptin receptor (OBR) on the prognosis of early-stage breast cancers. Cancer Res Treat. 2006;38(3):126–32.PubMedCrossRef

Revillion F, Charlier M, Lhotellier V, Homez L, Giard S, Baranzelli MC, et al. Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res. 2006;12:2088–94.PubMedCrossRef

10.

Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ. 2007;335:1134.PubMedCrossRef

11.

Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van Patten C, Dunn BP, et al. Waist to hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158:963–8.PubMedCrossRef

12.

Hollmann M, Runnebaum B, Gerhard I. Impact of waist-hip-ratio and body-mass-index on hormonal and metabolic parameters in young, obese women. Int J Obes Relat Metab Disord. 1997;21:476–83.PubMedCrossRef

13.

Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdoğan M, et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine. 2004;27:58–65.PubMedCrossRef

14.

Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005;23:6037–42.PubMedCrossRef

15.

Garaulet M, Pérex-Llamas F, Fuente T, Zamora S, Tebar FJ. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol. 2000;143(5):657–66.PubMedCrossRef

16.

Artac M, Bozcuk H, Afacan B, Ozdogan M, Samur M. The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer treated with aromatase inhibitors. Breast. 2008;17:418–22.PubMedCrossRef

17.

WHO (World Health Organisation). Measuring obesity-classification and description of antropometric data. EUR/ICP/NUT 125-0612. V. Copenhagen: WHO Regional Office for Europe; 1988.

18.

Hu FB. Overweight and obesity in women: health risks and consequences. J Womens Health (Larchmt). 2003;12:163–72.CrossRef

19.

Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG. 2006;113:1160–6.PubMedCrossRef

20.

Jarde T, Perrier S, Vasson MP, Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin. Eur J Cancer. 2011;47:33–43.PubMedCrossRef

21.

Stattin P, Söderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat. 2004;86:191–6.PubMedCrossRef

22.

Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006;95(2):153–8.PubMedCrossRef

23.

Geisler J, Ekse D, Lonning PE. The aromatase inactivator exemestane decreases plasma leptin levels in postmenopausal breast cancer patients. AACR, 97th Annual Meeting, abstract 420, Washington; 2006.

24.

Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol. 2005;95:167–72.PubMedCrossRef

25.

Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol. 2006;102:232–40.PubMedCrossRef

26.

Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen-receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003;95:1467–76.PubMedCrossRef

27.

Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer. 2011;104(1):128–37.PubMedCrossRef

28.

Grossman ME, Ray A, Nkhata KJ, Malakhov DA, Rogozina OP, Dogan S, et al. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev. 2010;29(4):641–53.CrossRef

29.

Söderberg S, Ahren B, Eliasson M, Dinesen B, Olsson T. The association between leptin and proinsulin is lost with central obesity. J Intern Med. 2002;252:14–148.CrossRef

30.

Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–5.PubMedCrossRef

31.

Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf). 2007;66(3):440–6.CrossRef

Title: Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)
Authors: Mehmet Artac
Hakan Bozcuk
Aysel Kıyıcı
Orhan Onder Eren
Melih Cem Boruban
Mustafa Ozdogan
Publication date: 01-04-2013
Publisher: Springer Japan
Published in: Breast Cancer / Issue 2/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-011-0322-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

Power Doppler breast ultrasound: association of vascularization and ER/c-erbB-2 co-expression in invasive breast carcinoma

Establishment of a standardized gene-expression analysis system using formalin-fixed, paraffin-embedded, breast cancer specimens

The current status of positron emission mammography in breast cancer diagnosis

Clinical application of the one-step nucleic acid amplification method to detect sentinel lymph node metastasis in breast cancer

Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer